设为首页         

资讯内容 Content

[ESC2009]ACCOMPLISH的影响及单片复方制剂(SPC)在临床中的应用--Dahlof教授专访
国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

 编辑:国际循环网 时间:2009/9/3 19:00:00    加入收藏
 关键字:KYOTO HEART Dahlof 倍博特 阿利吉仑 

 


International Circulation:  What impact do you think the ACCOMPLISH study will have or should have?  You are an expert in Europe but with the upcoming JNC 8 guidelines from the United States and also the ESC and ESH hypertension guidelines?  DO you think it should change or will it help change guidelines?

国际循环:您认为ACCOMPLISH研究将会或应该会产生什么样的影响?作为欧洲的专家,您对美国即将颁布的JNC 8指南及ESC/ESH高血压指南有何看法?该研究是否会改变指南内容,或有助于修改指南?

Dahlof:  Already in the guidelines we have strong recommendations that you could start patients on a single pill combination if they are 20/10 from their goal.  It is not stated in figures in the European guidelines, what I quoted was the American guidelines but it is the same general message.  I think that the ACCOMPLISH trial will now make that message even stronger for the coming guidelines.  I think one thing that I can not predict is how the choice of the diuretics in the American guidelines will be phrased this time because they were very diuretic oriented in the JNC 7 and I know behind some scenes there is a huge debate of how to phrase this in the next guidelines.  But I think that the combination story will also appear in the new American guidelines.

Dahlof:我们已对指南提出强烈建议,若想降低血压20/10,最好起始采用单药联合疗法。欧洲指南中并没有类似陈述,我引用的是美国指南中的内容。我认为ACCOMPLISH试验更确信了这一点,为即将颁布的指南提供依据。有一点我无法确定,就是美国指南将如何选择利尿剂,因为JNC 7曾力荐使用利尿剂,据我所知对本次指南将如何选择利尿剂的争议很大。但无论如何,新版美国指南还将纳入联合疗法。



上一页  [1]  [2]  [3]  [4]  下一页

 
京ICP备15014970号-5   国际循环 版权所有  2008-2022 icirculation.com  All Rights Reserved